Cedar Hill Associates’s Biogen BIIB Stock Holding History

Cedar Hill Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-625	Closed	-$220K	–	111
2018 Q3	$220K	Buy	+625	New	+$215K	0.05%	109

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cedar Hill Associates's BIIB Position: Q4 2018 in Review

Cedar Hill Associates sold out of Biogen (BIIB) in Q4 2018, closing a stake of 625 shares — an estimated $220K sold.

Cedar Hill Associates first reported a position in BIIB in Q3 2018 and held it in 1 quarter. The position peaked at $220K in Q3 2018. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Cedar Hill Associates reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Cedar Hill Associates sold 625 Biogen shares in Q4 2018, an estimated $220K.
Cedar Hill Associates first reported a position in Biogen in Q3 2018 and held it in 1 quarter.
Cedar Hill Associates's Biogen position peaked at $220K in Q3 2018.
1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Cedar Hill Associates's 13F filing for Q4 2018, filed 13 Feb 2019.